Previous 10 | Next 10 |
NEWARK, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that multiple Phase 2 and Phase 3 st...
NEWARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audi...
Gainers: Avadel Pharmaceuticals (AVDL) +31%. AlloVir (ALVR) +7%. Redbox Entertainment (RDBX) +6%. CymaBay Therapeutics (CBAY) +5%. Harpoon Therapeutics. (HARP) +5%. Losers: Protagonist Therapeutics (PTGX) -41%. Nkarta (NKTX) -6%. Provention Bio (PRVB...
Gainers: Evelo Biosciences, Inc. (EVLO) +5%. CymaBay Therapeutics Inc. (CBAY) +5%. Allakos Inc. (ALLK) +5%. Diversified Healthcare Trust (DHC) +4%. Angi Inc. (ANGI) +3%. Losers: Dogness (International) Corporation (DOGZ) -5%. MaxCyte, Inc. (MXCT) -4%. FTC Solar, Inc. (FTCI...
CymaBay Therapeutics Inc. (NASDAQ:CBAY) traded today at a new 52-week high of $15.58. So far today approximately 116.5 million shares have been exchanged, as compared to an average 30-day volume of 401,000 shares. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. It...
CymaBay Therapeutics (NASDAQ:CBAY) announced results from the Phase 2, 52-week study of Seladelpar in patients with primary biliary cholangitis (PBC). The company said the mid-stage study examined the efficacy and safety of seladelpar in adults with PBC who were receiving or intolerant to fir...
NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the Phase 2, 52-...
CymaBay Therapeutics, Inc. (CBAY) Q4 2021 Earnings Conference Call March 17, 2022 16:30 ET CompanyParticipants Paul Quinlan - General Counsel Sujal Shah - President & Chief Executive Officer Daniel Menold - Vice President of Finance Charles McWherter - Chief Scientific Officer Dennis Kim ...
Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q4 2021 Earnings Call Mar 17, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q4 2021 Earnings Call Transcript...
NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to it...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...